Phase II clinical trial of celecoxib for prevention of sporadic colorectal adenomas; contractor: brigham & women's hospital; principal investigator: monica bertagnolli, MD; contracting officer's…
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN261201000082C
- Awardee
-
Brigham & Womens Hospital Inc. UEI QN6MS4VN7BD1 Part of Partners Healthcare System Incorporated
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,903,738
Award facts
- Opportunity
-
- N01CN0503658 Solicitation number
- Contract value 100% obligated
- $1,903,737.98 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Cost No Fee
- Place of performance
- Boston, MA 02115, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$5,410 | |
| Original award | $1,909,148 |
About this award
The National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, awarded a $1,903,737.98 definitive cost-no-fee contract to Brigham & Women's Hospital in Boston, Massachusetts. The contract is for a Phase II clinical trial of celecoxib for the prevention of sporadic colorectal adenomas, with Dr. Monica Bertagnolli serving as the Principal Investigator and Dr. Asad Umar as the Contracting Officer's Technical Representative. The contract does not have a small business set-aside designation. Brigham & Women's Hospital is a subsidiary of the larger Partners Healthcare System Incorporated, a major integrated healthcare system that conducts extensive biomedical and clinical research through federal contract and grant awards. This contract supports the NCI's efforts to advance cancer prevention research.
Description
Phase II clinical trial of celecoxib for prevention of sporadic colorectal adenomas; contractor: brigham & women's hospital; principal investigator: monica bertagnolli, MD; contracting officer's technical representative: asad umar, MD
Quick answers
Who was awarded contract HHSN261201000082C?
HHSN261201000082C was awarded to Brigham & Womens Hospital Inc. by National Cancer Institute (National Institutes of Health) on October 1, 2009.
How much is contract HHSN261201000082C worth?
The government has obligated $1,903,738 on HHSN261201000082C.
Was contract HHSN261201000082C competed?
The extent of competition for HHSN261201000082C was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award